Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00518882 · ClinicalTrials.gov registry record · Phase 3
Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 467
- Enrollment target
NCT00518882 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 467 participants.
The verdict
NCT00518882, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 467 participants
- Enrollment target
Study Summary
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the effect on glycaemic control of liraglutide or exenatide when added to subject's ongoing OAD (oral anti-diabetic drug) treatment of either metformin, sulphonylurea or a combination of both in subjects with type 2 diabetes. Two trial periods: A 26 week randomised, followed by a 52 week extension (14 + 38 weeks) where all subjects received liraglutide + OAD after previous randomisation to either liraglutide or exenatide, both combined with OAD treatment.
Interventions
- DRUG liraglutide
- DRUG exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 467 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00518882
The ClinicalTrials.gov registry entry for NCT00518882 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 467 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which liraglutide is the first listed.
NCT00518882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00518882 about?
NCT00518882 is a clinical study titled "Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes". This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the effect on glycaemic control of liraglutide or exenatide when added to subject's ongoing OAD (oral anti-diabetic drug) treatment of either metformin, sulphonylurea or a combination of bot...
What is the current status of trial NCT00518882?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 467 participants. The study started on 2007-08. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00518882?
The interventions under investigation include: liraglutide (DRUG), exenatide (DRUG).
Who is sponsoring clinical trial NCT00518882?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.